Beigene Ltd
ONC244.900USD
-11.260-4.40%
收盤 04/25, 16:00（美東）報價延遲15分鐘
23.97B總市值
虧損本益比TTM
關於 Beigene Ltd 公司
百濟神州有限公司是一家全球生物科技公司，致力於爲全球癌症患者發現和開發腫瘤治療藥物。該公司已發現和開發了三種獲批藥物，包括 BRUKINSA，一種用於治療各種血癌的布魯頓酪氨酸激酶小分子抑制劑；TEVIMBRA（替雷利珠單抗），一種用於治療各種實體瘤和血癌的抗 PD-1 抗體免疫療法；以及帕米帕尼，一種選擇性聚 ADP-核糖聚合酶 1 (PARP1) 和 PARP2 小分子抑制劑。該公司已獲准在美國、中華人民共和國（中國）、歐盟、英國、加拿大、澳大利亞和其他國際市場銷售 BRUKINSA；在歐盟和中國銷售替雷利珠單抗；在中國銷售帕米帕尼。該公司還專注於在安進公司 (Amgen Inc.) 的獨家許可下在中國商業化 XGEVA、BLINCYTO、KYPROLIS 等抗癌藥物。
公司簡介
公司代碼ONC
公司名稱Beigene Ltd
上市日期Feb 03, 2016
成立日期2010
CEOMr. John Victor Oyler
員工數量11000
證券類型Ordinary Share
年結日Feb 03
公司地址c/o Mourant Governance Services (Cayman)
城市GRAND CAYMAN
上市交易所The Toronto Stock Exchange
國家Cayman Islands
郵編KY1-1108
電話13459494123
網址https://www.beigene.com/
公司代碼ONC
上市日期Feb 03, 2016
成立日期2010
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Xiaobin Wu ,
Xiaobin Wu ,
President, Chief Operating Officer, General Manager - China
President, Chief Operating Officer, General Manager - China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Director
Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Xiaodong Wang, Ph.D.
Dr. Xiaodong Wang, Ph.D.
Co-Founder, Non-Executive Director
Co-Founder, Non-Executive Director
--
--
Mr. Chan Lee, J.D.
Mr. Chan Lee, J.D.
Senior Vice President, General Counsel
Senior Vice President, General Counsel
--
--
MR. Aaron Rosenberg
MR. Aaron Rosenberg
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Michael J. Goller
Mr. Michael J. Goller
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Xiaobin Wu ,
Xiaobin Wu ,
President, Chief Operating Officer, General Manager - China
President, Chief Operating Officer, General Manager - China
16.36K
--
Ms. Shalini Sharp
Ms. Shalini Sharp
Director
Director
--
--
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Dr. Corazon Dating (Corsee) Sanders, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Han (Margaret) Dugan, M.D.
Dr. Han (Margaret) Dugan, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Qingqing (Michael) Yi
Mr. Qingqing (Michael) Yi
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Alessandro Riva, M.D.
Dr. Alessandro Riva, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
收入明細
單位: USD更新時間: 4月6日 週日
單位: USD更新時間: 4月6日 週日
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
地區USD
名稱
營收
佔比
United States
1.96B
51.37%
China
1.41B
37.04%
Europe
362.63M
9.52%
ROW
78.81M
2.07%
業務
地區
業務USD
名稱
營收
佔比
Product
3.72B
97.62%
BRUKINSA
2.64B
69.40%
Tislelizumab
620.84M
16.29%
XGEVA
224.40M
5.89%
BLINCYTO
74.33M
1.95%
Other
-3.47B
-91.15%
股東統計
更新時間: 4月26日 週六
更新時間: 4月26日 週六
持股股東
股東類型
持股股東
股東統計
佔比
Amgen Inc
19.15%
Baker Bros. Advisors LP
8.90%
Capital International Investors
6.18%
PRIMECAP Management Company
5.16%
Baillie Gifford & Co.
3.71%
Other
56.90%
持股股東
股東統計
佔比
Amgen Inc
19.15%
Baker Bros. Advisors LP
8.90%
Capital International Investors
6.18%
PRIMECAP Management Company
5.16%
Baillie Gifford & Co.
3.71%
Other
56.90%
股東類型
股東統計
佔比
Investment Advisor
24.19%
Corporation
19.18%
Hedge Fund
10.24%
Investment Advisor/Hedge Fund
5.05%
Sovereign Wealth Fund
2.00%
Research Firm
0.94%
Pension Fund
0.17%
Bank and Trust
0.10%
Family Office
0.02%
Other
38.11%
機構持股
更新時間: 1月20日 週一
更新時間: 1月20日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
541
67.04M
67.87%
+1.41M
2024Q4
575
70.01M
71.38%
+1.65M
2024Q3
603
67.03M
68.90%
-2.04M
2024Q2
601
66.99M
69.35%
-2.19M
2024Q1
621
66.56M
67.86%
-955.35K
2023Q4
626
65.12M
66.49%
-3.71M
2023Q3
632
67.27M
67.88%
-2.05M
2023Q2
655
66.79M
67.58%
-3.13M
2023Q1
655
67.68M
71.16%
-4.10M
2022Q4
657
69.40M
73.25%
-5.85M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Amgen Inc
18.94M
19.16%
--
--
Feb 20, 2025
Baker Bros. Advisors LP
8.80M
8.9%
-732.83K
-7.69%
Feb 28, 2025
Capital International Investors
6.11M
6.18%
-317.72K
-4.94%
Dec 31, 2024
PRIMECAP Management Company
5.10M
5.16%
+124.61K
+2.51%
Dec 31, 2024
Baillie Gifford & Co.
3.67M
3.71%
-34.56K
-0.93%
Dec 31, 2024
Fidelity Management & Research Company LLC
1.78M
1.8%
+174.46K
+10.84%
Dec 31, 2024
Temasek Holdings Pte. Ltd.
1.53M
1.54%
-863.25K
-36.14%
Dec 31, 2024
T. Rowe Price Associates, Inc.
1.49M
1.51%
+109.68K
+7.93%
Dec 31, 2024
T. Rowe Price International Ltd
1.44M
1.46%
+127.40K
+9.67%
Dec 31, 2024
HHLR Advisors, Ltd.
1.32M
1.34%
-2.48M
-65.19%
Mar 03, 2025
查看更多
持股ETF
更新時間: 4月6日 週日
更新時間: 4月6日 週日
機構名稱
佔比
First Trust NYSE Arca Biotechnology Index Fund
4.79%
Tema Oncology ETF
4.29%
Virtus LifeSci Biotech Products ETF
2.43%
Global X Aging Population ETF
2.13%
VanEck Biotech ETF
2.09%
iShares Health Innovation Active ETF
1.49%
iShares Biotechnology ETF
1.39%
Invesco Nasdaq Biotechnology ETF
1.15%
ProShares Ultra Nasdaq Biotechnology
1.14%
National Security Emerging Markets Index ETF
0.92%
查看更多
First Trust NYSE Arca Biotechnology Index Fund
佔比4.79%
Tema Oncology ETF
佔比4.29%
Virtus LifeSci Biotech Products ETF
佔比2.43%
Global X Aging Population ETF
佔比2.13%
VanEck Biotech ETF
佔比2.09%
iShares Health Innovation Active ETF
佔比1.49%
iShares Biotechnology ETF
佔比1.39%
Invesco Nasdaq Biotechnology ETF
佔比1.15%
ProShares Ultra Nasdaq Biotechnology
佔比1.14%
National Security Emerging Markets Index ETF
佔比0.92%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據